Faron Pharmaceuticals: Faron Announces Extension to its Key Patent Family around Bexmarilimab and Targeting Clever-1 in Cancers with a New US Patent Granted

• Faron has been granted a patent for treatment of Clever-1 positive cancers with bexmarilimab and related structures in the USA.

• This extends key patent rights around bexmarilimab from an initial 2037 to 2040 in the USA.

TURKU, FI / ACCESS Newswire / August 8, 2025 / Faron Pharmaceuticals Ltd. (AIM:FARN)(First North:FARON), a clinical-stage biopharmaceutical company focused on tackling cancers through novel immunological pathways, today announces that the United States Patent and Trademark Office has granted a new US Patent, No. 12,371,486 for treatment of Clever-1 positive cancers with bexmarilimab and related structures that would bind to Clever-1 molecule for the wanted re-programming effect.

The patent is granted based on divisional application from the original "composition of matter" patent covering the structure of bexmarilimab. The original application included the composition matter claimsas well as the treatment method. The new granted patent covers treating cancers that have Clever-1 positive cells in the tumour microenvironment with such structures. As previously announced a patent covering the composition of matter of bexmarilimab was already granted four years ago with patent life up to 2037 without extensions. Based on the long application process of the division application, the term of the newly granted patent has been adjusted beyond the standard twenty years lasting until February 2040.

"This significantly extends our key patent life on the use of bexmarilimab for the treatment of relevant cancers, that have Clever-1 positive tumour associated macrophages or blasts cells, such as in AML & MDS.", says Faron's CEO Juho Jalkanen. "The patent family around targeting Clever-1 in cancer is strong and we believe bexmarilimab will enjoy a long patent life once marketed, given how far it is in clinical development already", continues Dr. Jalkanen.

For more information, please contact:

IR Partners, Finland (media)
Riina Tuominen
[phone]
[e-mail]

Kare Laukkanen
[phone] / [phone]
[e-mail]

FINN Partners, US (media)
Alyssa Paldo
[phone]
[e-mail]

Cairn Financial Advisers LLP, Nominated Adviser and Broker
Sandy Jamieson, Jo Turner
Phone: [phone]

Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: [phone]
Jukka Järvelä
Phone: [phone]

About BEXMAB

The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About bexmarilimab

Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd.

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab , a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com .

Forward-Looking Statements

Certain statements in this announcement are, or may be deemed to be, forward-looking statements. Forward looking statements are identified by their use of terms and phrases such as "believe", "could", "should", "expect", "hope", "seek", "envisage", "estimate", "intend", "may", "plan", "potentially", "will" or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

A number of factors could cause actual results to differ materially from the results and expectations discussed in the forward-looking statements, many of which are beyond the control of the Company. In addition, other factors which could cause actual results to differ materially include the ability of the Company to successfully license its programs within the anticipated timeframe or at all, risks associated with vulnerability to general economic and business conditions, competition, environmental and other regulatory changes, actions by governmental authorities, the availability of capital markets or other sources of funding, reliance on key personnel, uninsured and underinsured losses and other factors. Although any forward-looking statements contained in this announcement are based upon what the Directors believe to be reasonable assumptions, the Company cannot assure investors that actual results will be consistent with such forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on forward-looking statements. Subject to any continuing obligations under applicable law or any relevant AIM Rule requirements, in providing this information the Company does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in events, conditions or circumstances on which any such statement is based.

SOURCE: Faron Pharmaceuticals

View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/faron-announces-extension-to-its-key-patent-family-around-bexmarilimab-and-targeting-1058296